ABVC BioPharma (ABVC) and The Competition Financial Comparison

ABVC BioPharma (NASDAQ:ABVC) is one of 956 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare ABVC BioPharma to similar companies based on the strength of its analyst recommendations, valuation, institutional ownership, risk, earnings, profitability and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for ABVC BioPharma and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	0	1	0	0	2.00
ABVC BioPharma Competitors	5077	16472	41264	777	2.59

As a group, “Pharmaceutical preparations” companies have a potential upside of 72.95%. Given ABVC BioPharma’s peers stronger consensus rating and higher probable upside, analysts plainly believe ABVC BioPharma has less favorable growth aspects than its peers.

Profitability

This table compares ABVC BioPharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	-1,607.06%	-477.58%	-121.75%
ABVC BioPharma Competitors	-2,254.25%	-338.71%	-33.32%

Volatility & Risk

ABVC BioPharma has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, ABVC BioPharma’s peers have a beta of 0.96, suggesting that their average share price is 4% less volatile than the S&P 500.

Earnings & Valuation

This table compares ABVC BioPharma and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ABVC BioPharma	$765,644.00	-$16.42 million	-0.28
ABVC BioPharma Competitors	$8.96 billion	$205.18 million	-5.08

ABVC BioPharma’s peers have higher revenue and earnings than ABVC BioPharma. ABVC BioPharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

24.6% of ABVC BioPharma shares are held by institutional investors. Comparatively, 40.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 39.0% of ABVC BioPharma shares are held by insiders. Comparatively, 15.2% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

ABVC BioPharma peers beat ABVC BioPharma on 10 of the 13 factors compared.

About ABVC BioPharma

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.